Quality by Design for Biologics and Biosimilars - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Quality by Design for Biologics and Biosimilars
The author provides an overview of QbD implmentation for biopharmaceuticals.

Pharmaceutical Technology
Volume 35, Issue 3, pp. 64-68

QbD's future in biologics

Looking ahead, certain technologies and processes will need to be refined for QbD implementation in the biopharmaceutical industry (10).

High-throughput approaches. As noted, QbD implementation requires extensive process and product knowledge (6, 7). Acquiring this level of understanding requires extensive experimentation. In the current environment, where cost needs to be controlled, use of high-throughput tools and approaches has emerged as a means of saving considerable costs on needed chemicals, feed material, product, equipment, and most importantly, staff (11). There is a strong likelihood that widespread use of high-throughput tools and approaches will dramatically change how the biotech industry performs the various activities required for product and process development and commercialization in the next decade.

Nonclinical studies as predictors of safety and/or efficacy. Industry at present relies heavily on clinical studies to assess drug safety and efficacy. Although advances have been made in the past decade with regard to industry's ability to model safety and/or efficacy through nonclinical studies, more is needed to reduce reliance on human clinical trials (10). Developments in the way drugs are discovered and in molecular design are expected.

Use of statistical approaches and risk management. QbD implementation requires extensive information about the product and its manufacturing process. However, in view of the large number of variables and attributes that interplay to impact safety and efficacy of a biotechnology product, it is not possible to evaluate the effect of every variable. Statistical approaches, such as design of experiments (DOE) and multivariate data analysis (MVDA), along with risk management tools such as the Failure Modes and Effects and Analysis (FMEA), can help to ensure that resources are spent on the most important tasks.

Global adoption. Thus far, QbD implementation has been limited to large and mid-size biotechnology companies in the US and the Europe. As manufactures based in India and China start producing follow-on biologics for the European and the US markets, they too will start imbibing QbD principles. Some of these companies have already started this alignment. In the near future, the biotechnology industry is likely to see a major overhaul of scientific and quality-based manufacturing approaches as well as a more global adoption of QbD principles.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here